Sarepta wants to raise $100M in stock offering

Fresh off a big boost to the chances that Sarepta Therapeutics’ most promising drug will be approved in the next year or so to treat Duchenne’s muscular dystrophy, the Cambridge biotech announced plans to raise $100 million in a stock offering, which would bring its total cash to more than $330 million...